Radiation Technique Tested in Gynaecological Cancers Including Cervical Cancer
Tests a special radiation technique in adults with cervical cancer or pelvic recurrence.
Plain-language title generated from the registry record
Registry title: Spatially Fractionated Radiation Treatment for Gynaecological Cancers
Key facts
- Where
- Navi Mumbai, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06644846, who can take part
Where in India
- ACTREC Tata Memorial CentreNavi Mumbai, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tata Memorial Hospital
- Trial code
- NCT06644846
- Record updated
- 20 February 2026
- Original description
This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.Read full original descriptionShow less
A Prospective Study of Spatially Fractionated Radiation Treatment Using Rapid Rod Technique for Gynaecological Cancers
This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.
The study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.
Inclusion: Patients with cervical cancer post EBRT, with expected suboptimal brachytherapy dose coverage due to-; Aberrant uterine or pelvic anatomy leading to difficulty in localization of the cervical OS or negotiation of the uterine canal accurately by two independent clinicians in up to two procedures; Large residual disease at the time of brachytherapy with anticipated suboptimal target coverage either determined in clinic based on pre-brachytherapy imaging or at dose planning (e.g. figure 2); Very narrow vaginal canal not accommodating even the smallest intracavitary or vaginal cylinder applicators; Patients with inoperable endometrial cancer not suitable for anaesthesia or have anticipated suboptimal coverage of target volume at brachytherapy as identified on pre-brachytherapy imaging obtained after EBRT; Patients with large pelvic recurrences after surgery and/or (chemo) radiation, not amenable to surgical salvage or brachytherapy after salvage EBRT due to reasons specified in item 1; Patients with contraindications to anaesthesia for brachytherapy with sufficient risk of on-table or post procedure adverse events.
Exclusion: Any pre-existing fistula in bladder or rectum; Pelvic prosthesis; Refusal to provide consent.